Cancer detection that's as determined as you are.
Facing cancer takes courage. clonoSEQ helps doctors detect, quantify, and monitor small amounts of cancer known as measurable (or minimal) residual disease (MRD) to inform treatment throughout a patient’s care. So you can approach cancer measurement with the same strength and bravery as cancer treatment.
This page is intended for a US-based audience.
clonoSEQ® is an FDA-cleared test used to detect measurable residual disease (MRD) in bone marrow from patients with multiple myeloma or B-cell acute lymphoblastic leukemia (B-ALL) and blood or bone marrow from patients with chronic lymphocytic leukemia (CLL). clonoSEQ is also available for use in other lymphoid cancers and specimen types as a CLIA-validated laboratory developed test (LDT).
clonoSEQ is only available by prescription from a licensed healthcare professional. Results may vary. Talk to your healthcare provider to see if clonoSEQ testing is right for you. For important information about the FDA-cleared uses of clonoSEQ including test limitations, please visit clonoSEQ.com/technical-summary.